KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag™ and KineMarker™) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration.
KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck, Merck KGaA, Organon and Roche.
For further information about KineMed, please visit: http://www.kinemed.com/
Company: |  | KineMed, Inc. |
|  | ||
Headquarters Address: | 5980 Horton Street | |
| Suite 400 | ||
| Emeryville, CA 94608 | ||
|  | ||
Main Telephone: | +1-510-655-6525 | |
|  | ||
Website: | www.kinemed.com | |
|  | ||
Type of Organization: | Private | |
|  | ||
Industry: | Biotechnology | |
|  | ||
Key Executives: | President & Chairman: David Fineman | |
CEO: Robert Stein | ||
|  | ||
Investor Relations | ||
Contact: | David Fineman | |
Phone: | +1-510-655-6525 | |
Email: | dfineman@kinemed.com |
